Nuclear gatekeeper could block undruggable prostate cancer targets

Certain molecular drivers of cancer growth are “undruggable” — it has been nearly not possible to develop chemicals that may block their action and stop cancer growth. several of those molecules operate by passing cancer-promoting data through a gate within the nucleus, wherever the directions are disbursed. Researchers at the poet Kimmel Cancer Center — President of the United States Health have found the simplest way to dam the nuclear gates employed by these molecules, and show that this inhibition will halt aggressive prostatic adenocarcinoma in mice bearing human tumors.

The analysis, co-led by speedwell Rodriguez-Bravo, Ph.D., and Josep Domingo-Domenech, MD, Ph.D., revealed in Cell August nine, 2018. [1]

Sentinel node evaluation in prostate cancer

Sentinel node (SLN) based mostly girdle node dissection (PLND) in adenocarcinoma (PCa) is appealing over the time, value and morbidity classically attributed to traditional PLND throughout radical extirpation. The initial report of the feasibleness of the SLN idea in adenocarcinoma was nearly twenty years past. However, PLND supported the SLN idea, either SLN diagnostic test of one node or targeted SLN dissection of multiple nodes, remains thought-about investigational in PCa. [2]

Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy

Purpose: The current study aims to judge each early and late toxicity profiles of patients receiving immediate surgical radiation (RT; adjuvant RT or additive RT) compared to salvage RT.

Methods: we tend to evaluate 253 patients with adenocarcinoma treated with either immediate surgical  (adjuvant RT, n = 42; additive RT, n = 39) or salvage RT (n = 137). 35 patients received salvage treatment, however, didn’t reach a surgical prostate specific substance (PSA) level <0.1 ng/ml and thus were excluded from analysis. [3]

Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer

Prostate cancer can be controlled by androgen‐hormone treatment until cancer becomes refractory. it’s believed that internal secretion sensitivity is basically captivated with sex hormone receptor (AR) activity. Here, we found the histone demethylase KDM7A which demethylates histone H3K27 to be overexpressed in enzalutamide resistant castration‐resistant prostate cancer cell line C4‐2b and investigated the molecular mechanism whereby sex hormone receptor activity is regulated by KDM7A. We engineered AR‐positive LNCaP cells to stably express a short‐hairpin RNA against KDM7A mRNA from a lentiviral vector. [4]

Hypofractionated Radiotherapy for Localized Prostate Cancer: Clinical Outcome (Mansoura University)

Purpose: during this study, we have a tendency to describe the effectuality and safety of hypofractionated irradiation in treating patients with localized adenocarcinoma.

Patients and Methods: a complete of seventy patients diagnosed with localized (T1-T2) adenocarcinoma. Low and intermediate risk teams were prospectively recruited between Nov 2012 and Nov 2016. Patients were treated with hypo-fractionated RT of sixty Gy in twenty fractions over four weeks. sex hormone deprivation medical care was allowable for intermediate risk patients. the first outcome was organic chemistry relapse-free survival that outlined because of the nadir PSA post-radiotherapy and a pair of ng/ml in line with PHOENIX criteria. Overall survival and treatment toxicity were secondary finish points. [5]

Reference

[1] Nuclear gatekeeper could block undruggable prostate cancer targets

Date: August 9, 2018, Source: Thomas Jefferson University (web link)

[2] Sentinel node evaluation in prostate cancer

Narayanan R, Wilson TG. Sentinel node evaluation in prostate cancer. Clinical & Experimental Metastasis. 2018:1-5. (web link)

[3] Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy

Vogel MM, Kessel KA, Gschwend JE, Weichert W, Wilkens JJ, Combs SE. Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy. Strahlentherapie und Onkologie. 2018:1-4. (web link)

[4] Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer

Lee KH, Hong S, Kang M, Jeong CW, Ku JH, Kim HH, Kwak C. Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer. International Journal of Cancer. (web link)

[5] Hypofractionated Radiotherapy for Localized Prostate Cancer: Clinical Outcome (Mansoura University)

Abeer Hussien Anter1* and Mohamed Farouk Akl1

1Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Egypt. (web link)

Leave a Reply

Your email address will not be published. Required fields are marked *